ArctxLogoVert

Developing The World’s First Medical Device

Therapy for Acute Pancreatitis

ArctxLogoVert

Developing The World’s First Device Therapy

for Acute Pancreatitis

Chill-AP Pivotal Study launching early 2026 based on completion of successful First in Human Study

Arctx Medical is focused on developing innovative medical device therapies to improve outcomes for patients suffering from Acute Pancreatitis

 

Non-Surgical. Minimally Invasive.

 

The Human Cost – Acute Pancreatitis

 

2.8 Million

cases of acute pancreatitis globally

Leading Cause of Hospitalization

amongst gastrointestinal disorders in the United States

No New Commercially Available Treatments for Acute Pancreatitis

Pain meds, fluids, and nutrition for mild cases

6 days

The average length of hospital stay

Prolonged Hospital Stay for Severe Pancreatitis

for 25% of pancreatitis patients

5% mortality rate